Chicago (Reuters) – Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co’s cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations. Bristol... More »
We use cookies!
By using this site you agree to the use of cookies, more info.